fluoxetine has been researched along with pergolide in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamblin, MW; Monsma, FJ; Shen, Y; Sibley, DR; Ward, RP | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lemberger, L | 1 |
| Konishi, H; Nagai, K | 1 |
| Inoue, T; Konishi, H; Nagai, K | 1 |
1 review(s) available for fluoxetine and pergolide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for fluoxetine and pergolide
| Article | Year |
|---|---|
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Blotting, Northern; Brain Chemistry; Cell Line; Cloning, Molecular; DNA; GTP-Binding Proteins; Lysergic Acid Diethylamide; Molecular Sequence Data; Polymerase Chain Reaction; Psychotropic Drugs; Rats; Receptors, Serotonin; RNA; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection | 1993 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Of mice and men: the extension of animal models to the clinical evaluation of new drugs.
Topics: Animals; Drug Evaluation; Drug Evaluation, Preclinical; Ergolines; Fluoxetine; Humans; Models, Biological; Pergolide; Pharmacology, Clinical; Rats | 1986 |
Effect of fluoxetine and pergolide on expression of nucleoside transporters and nucleic-related enzymes in mouse brain.
Topics: Adenosine Kinase; Animals; Apyrase; Brain; Dopamine Agonists; Fluoxetine; Male; Mice; Mice, Inbred Strains; Nucleoside Transport Proteins; Pergolide; Protein Isoforms; Real-Time Polymerase Chain Reaction; RNA, Messenger; Selective Serotonin Reuptake Inhibitors | 2014 |
Increased gene expression of glucose transporters in the mouse brain after treatment with fluoxetine and pergolide.
Topics: Animals; Brain; Fluoxetine; Gene Expression; Glucose Transport Proteins, Facilitative; Male; Mice; Pergolide; RNA, Messenger | 2014 |